New Study Shows INGREZZA® (valbenazine) Capsules Enable All Patients to Reach Therapeutic Dose from Day One
Neurocrine Biosciences, a leading biopharmaceutical company, recently announced the presentation of new data from a real-world study showcasing the effectiveness of INGREZZA® (valbenazine) capsules in treating tardive dyskinesia (TD). The study was conducted as part of the Academy of Managed Care Pharmacy 2025 Annual Meeting in Houston, Texas.
All Patients Achieved Therapeutic Dose with INGREZZA®
The retrospective cohort study revealed that every patient who began treatment with INGREZZA® capsules reached the therapeutic dose on the first day. This is a significant improvement compared to deutetrabenazine, another TD treatment, where only about half of the patients were able to achieve the therapeutic dose within the first six months.
Implications for Patients
For individuals diagnosed with TD, this new finding can lead to improved treatment outcomes and faster relief from symptoms. Since reaching the therapeutic dose from the start of treatment, patients can expect more consistent symptom control and better quality of life.
- Faster relief from TD symptoms
- Consistent symptom control
- Improved quality of life
Global Impact
The implications of this research extend beyond individual patients. This data may influence healthcare systems, payers, and policymakers in their decision-making processes regarding TD treatments. By demonstrating the ability of INGREZZA® capsules to enable all patients to reach the therapeutic dose from day one, the study could lead to increased access to effective TD treatments for a larger population.
- Influence on healthcare systems, payers, and policymakers
- Increased access to effective TD treatments
Conclusion
The new data presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting highlights the benefits of using INGREZZA® capsules for the treatment of tardive dyskinesia. With all patients reaching the therapeutic dose on the first day, this groundbreaking finding could lead to improved treatment outcomes, faster relief from symptoms, and better quality of life for individuals with TD. Furthermore, the global impact of this research could result in increased access to effective TD treatments for a larger population, ultimately leading to better healthcare outcomes for all.
As we continue to learn more about the potential of INGREZZA® capsules, it is essential to stay informed about the latest developments in the field of TD treatment. By staying up-to-date on the latest research, patients, caregivers, and healthcare professionals can make more informed decisions about their care and contribute to the ongoing advancements in the field.
